| Original language | English (US) |
|---|---|
| Pages (from-to) | 1276-1281.e1 |
| Journal | Journal of Pediatrics |
| Volume | 162 |
| Issue number | 6 |
| DOIs |
|
| State | Published - Jun 2013 |
| Externally published | Yes |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Pediatrics, Vol. 162, No. 6, 06.2013, p. 1276-1281.e1.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Comprehensive assessment of serious adverse events following immunization by health care providers
AU - Williams, S. Elizabeth
AU - Edwards, Kathryn M.
AU - Baxter, Roger P.
AU - Larussa, Philip S.
AU - Halsey, Neal A.
AU - Dekker, Cornelia L.
AU - Vellozzi, Claudia
AU - Marchant, Colin D.
AU - Donofrio, Peter D.
AU - Reimschisel, Tyler E.
AU - Berger, Melvin
AU - Gidudu, Jane F.
AU - Klein, Nicola P.
N1 - Funding Information: Supported by the CISA network through a subcontract with America's Health Insurance Plans (contract 200-2002-00732 from the Centers for Disease Control and Prevention). C.D. is a member of the Scientific Advisory Board of PharmaJet and is on Safety Monitoring Committees for HVTN and Pfizer. N.H. has received compensation for serving on Safety Monitoring Committees for Novartis and Merck, receives grant support from Merck , and received an honorarium for attending a meeting with Pfizer. N.K. and R.B. receive research grants from GlaxoSmithKline , Merck , Sanofi Pasteur , MedImmune , Novartis , and Pfizer . C.M. has served as an investigator for Merck, Pfizer, Novartis, MedImmune, Sanofi, and GSK, a consultant for GSK, Sanofi, and Novartis, and a speaker for Sanofi, Novartis, and Pfizer. P.L. has served on the Data Safety Monitoring Board for Novartis and receives limited funding from Merck . K.E. receives funding from the National Institutes of Health (Contract HHSN272200800007C) and CDC (Contracts U01 IP000488-02 and 200-2012-50430). M.B. is a salaried employee for CSL Behring and receives consulting fees for CISA and Sanofi-Aventis. P.D. is on the advisory board of DIME, CSL, Talecris, and Caridian. The other authors declare no conflicts of interest. Funding Information: Supported by the CISA network through a subcontract with America's Health Insurance Plans (contract 200-2002-00732 from the Centers for Disease Control and Prevention). C.D. is a member of the Scientific Advisory Board of PharmaJet and is on Safety Monitoring Committees for HVTN and Pfizer. N.H. has received compensation for serving on Safety Monitoring Committees for Novartis and Merck, receives grant support from Merck, and received an honorarium for attending a meeting with Pfizer. N.K. and R.B. receive research grants from GlaxoSmithKline, Merck, Sanofi Pasteur, MedImmune, Novartis, and Pfizer. C.M. has served as an investigator for Merck, Pfizer, Novartis, MedImmune, Sanofi, and GSK, a consultant for GSK, Sanofi, and Novartis, and a speaker for Sanofi, Novartis, and Pfizer. P.L. has served on the Data Safety Monitoring Board for Novartis and receives limited funding from Merck. K.E. receives funding from the National Institutes of Health (Contract HHSN272200800007C) and CDC (Contracts U01 IP000488-02 and 200-2012-50430). M.B. is a salaried employee for CSL Behring and receives consulting fees for CISA and Sanofi-Aventis. P.D. is on the advisory board of DIME, CSL, Talecris, and Caridian. The other authors declare no conflicts of interest.
PY - 2013/6
Y1 - 2013/6
UR - http://www.scopus.com/inward/record.url?scp=84880572565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880572565&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2013.01.028
DO - 10.1016/j.jpeds.2013.01.028
M3 - Comment/debate
C2 - 23452584
AN - SCOPUS:84880572565
SN - 0022-3476
VL - 162
SP - 1276-1281.e1
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 6
ER -